LifeArc and the EU-funded project, REMEDi4ALL, have announced a collaboration agreement to strengthen the partnership’s potential to transform and accelerate the repurposing of medicines in Europe.

Focusing on drug repositioning

The agreement reflects the increased interest in drug repositioning and repurposing as a faster, more cost-effective strategy to complement de novo drug development approaches. Such medicines repurposing holds particular promise for rare diseases which otherwise have no effective treatment options.

As a new Associated Partner, LifeArc brings extensive expertise in translational research, drug development, and downstream development to the REMEDi4ALL consortium. This new collaboration will enhance the platform’s ability to connect researchers, clinicians, regulators, funders, and patient organisations, and to accelerate the development and delivery of innovative repositioned and repurposed treatments options for those who need them most.

“This collaboration is a natural extension of LifeArc’s work to break down the barriers that prevent scientific breakthroughs from reaching those who need them most. Our expertise in translational research, drug development, and downstream development, combined with the REMEDi4ALL platform, will help to fast track the development of repurposed medicines that have the potential to transform the lives of people with rare diseases.”

Dr Joanna Davidge, Head of Funding, LifeArc

Alicia Soler Cantón, Scientific Programme Manager at EATRIS adds: “LifeArc shares the REMEDi4ALL vision. With over 30 years of experience in translational research and a strong interest in drug repurposing, their expertise will be invaluable in addressing medical challenges often neglected due to cost, complexity, or high-risk nature. Their impressive track-record in translational research will now greatly enhance the REMEDi4ALL platform, facilitating more equitable access to treatments for underserved patient groups.”